Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacotherapy for erectile dysfunction.

Andrew Feifer1, Serge Carrier

  • 1Division of Urology, McGill University, Jewish General Hospital, 3755 Cote Ste Catherine, E-9, Montreal, Quebec, H3A 1A1, Canada.

Expert Opinion on Investigational Drugs
|May 2, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadir.

Future oncology (London, England)·2026
Same author

Outcomes and Predictors of Recurrence and Survival in Surgically Resected Localized Chromophobe Renal Cell Carcinoma: Results from the Canadian Kidney Cancer Information System (CKCis).

Current oncology (Toronto, Ont.)·2026
Same author

Risk of metachronous upper tract urothelial carcinoma following non-muscle-invasive bladder cancer.

BJU international·2025
Same author

Development and International Evaluation of an Artificial Intelligence-based Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System to Predict Progression Risk and Improve Substratification for Non-muscle-invasive Bladder Cancer.

European urology·2025
Same author

GreenLight laser prostatectomy: Are outcomes sustainable after a decade of surgery? A single-center experience with up to 15 years' followup.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2025
Same author

Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial.

The Lancet. Oncology·2025
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
Same journal

Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges.

Expert opinion on investigational drugs·2026
Same journal

Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial.

Expert opinion on investigational drugs·2026
Same journal

The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis.

Expert opinion on investigational drugs·2026
Same journal

The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates.

Expert opinion on investigational drugs·2026
See all related articles

Advances in erectile dysfunction (ED) treatment focus on novel molecular targets. New therapies, including melanocortins, Rho-kinase inhibitors, and gene therapy, show promise beyond current phosphodiesterase inhibitors for ED.

Area of Science:

  • Pharmacology
  • Urology
  • Molecular Biology

Background:

  • Erectile dysfunction (ED) remains a significant health concern.
  • Current treatments primarily utilize phosphodiesterase inhibitors.
  • Understanding ED pathophysiology is crucial for developing new therapies.

Purpose of the Study:

  • To review recent advancements in the pharmacological treatment of ED.
  • To identify novel neuro-endocrine and molecular targets for ED therapy.
  • To explore emerging treatment modalities beyond existing options.

Main Methods:

  • Comprehensive literature search of MEDLINE and PubMed.
  • Inclusion of studies on novel mechanistic approaches for ED.
  • Evaluation of in vitro, animal, and in vivo experimental therapies.

Related Experiment Videos

Main Results:

  • Phosphodiesterase inhibitors are the current first-line ED treatment.
  • Emerging therapies like melanocortins and Rho-kinase inhibitors show promise.
  • Gene therapy approaches have demonstrated efficacy in preclinical and early human studies.

Conclusions:

  • Renewed interest in ED pathophysiology has identified new therapeutic targets.
  • Novel targets are expected to broaden treatment alternatives for ED.
  • Future ED management may include oral and genetic therapies.